NCT06210542View on ClinicalTrials.gov

Precise Treatment of Ceftazidime-Avibactam in Patients With CRO Infections Under the Guidance of TDM and PPK Model

Not yet recruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2026

Conditions
ECMOCarbapenem-Resistant Enterobacteriaceae Infection
Interventions
DRUG

ceftazidime avibactam

"Routine treatment dose for patients: the recommended intravenous dose for patients with creatinine clearance rate (eCrCL) \> 50ml/min was 2.5g (2g/0.5g), once every 8 hours, and the infusion time was 2 hours.~Patients with renal injury adjust the dosage according to eCrCL"

All Listed Sponsors
lead

Sichuan Provincial People's Hospital

OTHER

NCT06210542 - Precise Treatment of Ceftazidime-Avibactam in Patients With CRO Infections Under the Guidance of TDM and PPK Model | Biotech Hunter | Biotech Hunter